Considering that cognitive impairment in AD is more strongly associated with tau pathology than with Aβ deposition, further research is needed to elucidate APOA-I’s direct influence on tau pathogenesis and its potential to block Aβ-induced tauopathy in AD models. The gene discussed is MAPT; the disease is Alzheimer disease.